Covid-19 (Temas de Saúde Pública)

Estudo randomizado com cerca de 30.000 indivíduos mostrou que a vacina Novavax foi segura e teve eficácia geral de 90,4% contra infecções sintomáticas por Covid-19.

17 Dez, 2021 | 12:31h

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Comentários:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Conteúdo relacionado: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (vários artigos sobre o tema)

Covid-19: dados iniciais mostram que coriza, dor de cabeça e fadiga são os sintomas mais comuns da infecção pela variante Ômicron.

17 Dez, 2021 | 12:24h

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

Ver também: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

Comentário no Twitter

The UK government has been urged to update its list of symptoms for covid-19, after early data showed cold-like symptoms of a runny nose, headache, fatigue, sneezing, and sore throat were the most commonly reported by people with the new omicron variant https://t.co/n6OJYIDTgf

— The BMJ (@bmj_latest) December 16, 2021

Conselheiros do CDC recomendam o uso preferencial de vacinas mRNA contra COVID em vez da vacina da J&J.

17 Dez, 2021 | 12:20h

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

Opinião | Estratégias de vacinação contra COVID-19 devem focar na doença grave e na equidade global.

17 Dez, 2021 | 12:19h

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

Como as vacinas contra COVID moldaram 2021, em 8 gráficos.

17 Dez, 2021 | 12:17h

How COVID vaccines shaped 2021 in eight powerful charts – Nature

Modelagem da mortalidade por COVID-19 em 44 países: uso de máscaras pode reduzir as mortes.

16 Dez, 2021 | 13:08h

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Comentário: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Opinião | Cobertura vacinal desigual no mundo é o centro da atual crise da Covid-19.

16 Dez, 2021 | 13:02h

Unequal global vaccine coverage is at the heart of the current covid-19 crisis – The BMJ

M-A | Porcentagem global de infecções assintomáticas por SARS-CoV-2 é em torno de 40%.

15 Dez, 2021 | 12:48h

Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis – JAMA Network Open

Comentário: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay

[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.

15 Dez, 2021 | 12:47h

Comunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death